Why Is Ocular Therapeutix Stock Gaining Monday?
Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.
A different company's eye medicine didn't work as well as hoped, which makes investors more interested in Ocular Therapeutix's similar product instead. When one team stumbles, another team's chances look better by comparison.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.